Sequencing a newborn, and the three babies it missed
One in forty healthy babies gets flagged, and nearly half of that is one common enzyme variant that is usually silent. The number that matters more is three false negatives in 1,979.
The same technology is now being offered at the other end: sequencing healthy newborns. Two large programmes have published.
The larger one screened 4,000 newborns in New York and reported 3.7% screen positive. Before that number frightens anyone, look at what it was: of 151 positive findings, 92 were G6PD deficiency, a common enzyme variation that is usually silent and is managed by avoiding specific triggers.
The North Carolina programme did the arithmetic in the open. Of 1,979 newborns, 2.5% screened positive. G6PD variants alone were nearly half of all screen positives
. Remove G6PD and one gene that was on the panel for the wrong reason, and the rate falls to 0.8%. Just over half of the flags, 28 of 51, were true or probably true.
And now the part that matters most for this stage. That same programme reported three false negatives in 1,979 babies: a baby with sickle cell disease, a baby with late-onset Pompe disease whose real variant had been filtered out as uncertain and not reported, and a baby with congenital hypothyroidism.
Parents were asked what they took away. Among those who received a normal result and responded, attitudes were overwhelmingly positive, and yet only 60.9% demonstrated adequate knowledge of what the result actually meant. Two in five did not, among the most engaged parents in the programme.
Where this stands professionally. No US professional society recommendation that healthy newborns undergo genome screening was found in the medical databases searched for this guide as of August 2026. The people running the largest study describe the field as unsettled, raising concerns including acceptability, equity, and scalability.
Meanwhile it is being sold. One commercial service, read on 27 August 2026, offers Bringing genomic screening into routine pediatric care
and We're building a future where every child can benefit from genomic insights.
On the two pages read that day, neither the number of conditions screened, nor the price, nor what a normal result does not exclude was stated.
"What is on the panel that is common and mild, and can I decline that part?"
"If this comes back normal, which conditions could my baby still have?"